Beyondspring Inc (NASDAQ:BYSI) Short Interest Up 15.5% in May

Share on StockTwits

Beyondspring Inc (NASDAQ:BYSI) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 244,200 shares, a growth of 15.5% from the April 30th total of 211,400 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average daily trading volume, of 19,500 shares, the short-interest ratio is presently 12.5 days.

Shares of Beyondspring stock traded up $0.66 during trading on Wednesday, hitting $23.12. 19,837 shares of the stock were exchanged, compared to its average volume of 14,829. The stock has a market cap of $489.10 million, a P/E ratio of -9.55 and a beta of 0.81. Beyondspring has a 12-month low of $13.06 and a 12-month high of $27.80.

Beyondspring (NASDAQ:BYSI) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Beyondspring will post -1.82 earnings per share for the current year.

BYSI has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of Beyondspring in a research report on Monday, March 4th. Maxim Group cut shares of Beyondspring from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th.

ILLEGAL ACTIVITY NOTICE: “Beyondspring Inc (NASDAQ:BYSI) Short Interest Up 15.5% in May” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4380286/beyondspring-inc-nasdaqbysi-short-interest-up-15-5-in-may.html.

About Beyondspring

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Read More: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Atlas Copco  and Enviro Technologies  Head-To-Head Analysis
Atlas Copco and Enviro Technologies Head-To-Head Analysis
Smart Global  versus Micron Technology  Financial Review
Smart Global versus Micron Technology Financial Review
Head-To-Head Contrast: Newmont Goldcorp  versus Harmony Gold Mining
Head-To-Head Contrast: Newmont Goldcorp versus Harmony Gold Mining
Waterstone Financial  & Access National  Critical Comparison
Waterstone Financial & Access National Critical Comparison
Financial Survey: Sorrento Therapeutics  vs. Tenax Therapeutics
Financial Survey: Sorrento Therapeutics vs. Tenax Therapeutics
Canaccord Genuity Begins Coverage on Slack
Canaccord Genuity Begins Coverage on Slack


© 2006-2019 Ticker Report